{
    "nct_id": "NCT03632135",
    "official_title": "Standard Chemotherapy Versus Chemotherapy Chosen by Cancer Stem Cell Chemosensitivity Testing in the Management of Patients With Recurrent Glioblastoma Multiforme (GBM).",
    "inclusion_criteria": "1. Men and Women and members of all ethnic groups who are at least 18 years old at the time of enrollment are eligible for this trial;\n2. Informed consent obtained and signed;\n3. Willing and able to commit to study procedures including long-term follow-up visit(s);\n4. Histopathologically confirmed 2016-WHO grade III recurrent glioma, and grade IV recurrent glioblastoma (GBM), inclusive of Gliosarcoma\n5. In all cases, the diagnosis must be confirmed by a pathologist.\n6. Recurrent surgically resectable tumor and/or biopsy;\n7. Participants who have undergone surgical resection should have received an MRI or a scan after surgery in order to visualize residual tumor. If not, the operative report must be available;\n8. Prior to surgery there was imaging evidence of measurable progressive disease (PD);\n9. Start of radiotherapy, if indicated, must occur at least 2 weeks after surgery and/or biopsy;\n10. Estimated survival of at least 3 months;\n11. Hgb > 9 gm; absolute neutrophil count (ANC) > 1500/Î¼l; platelets > 100,000; Creatinine < 1.5 times the upper limit of laboratory normal value; Bilirubin < 2 times the upper limit of laboratory normal value; serum glutamate pyruvate transaminase (SGPT) or serum glutamate oxaloacetate transaminase (SGOT) < 3 times the upper limit of laboratory normal value;\n12. If indicated radiation therapy and chemotherapy must start within 8 weeks of tumor resection or biopsy.\n13. Bevacizumab (Avastin) is allowed. If indicated it should be initiated at least 4 weeks post craniotomy or biopsy if the wound has healed well without any drainage or cellulitis;\n14. The use of herbal preparation or tetrahydrocannabinol/cannabidiol is strongly discouraged, but not contraindicated;\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
    "exclusion_criteria": "1. Subjects with newly diagnosed GBM\n2. Pregnant women or nursing mothers cannot participate in the study. Women of childbearing age must have a negative pregnancy test within 72 hours prior to study entry. Women of childbearing potential must practice medically approved contraceptive precautions;\n3. Abnormal hematological results at inclusion with: Neutrophils < 1,500/mm3; Blood-platelets < 100,000/mm3\n4. Severe or chronic renal insufficiency (creatinine clearance â‰¤ 30 ml/min);\n5. Patient unable to follow procedures, visits, examinations described in the study;\n6. Any usual formal indication against imaging examinations (important claustrophobia, pacemaker);\n7. History of another malignancy in the previous 2 years, with a disease-free interval of < 2 years. Patients with prior history of in situ cancer or basal or squamous cell skin cancer, any time prior to screening, are eligible;\n8. OPTUNE device is not permitted in the study;\n9. Patients cannot participate to any clinical trials utilizing a liquid biomarker or imaging studies that impact the overall survival.",
    "miscellaneous_criteria": ""
}